Cargando…
Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
INTRODUCTION: Vidofludimus calcium has shown anti-inflammatory effects in clinical trials of autoimmune diseases and recently demonstrated antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We performed a double-blind, randomized, placebo-controlled, phase 2 tri...
Autores principales: | Vehreschild, Maria J. G. T., Atanasov, Petar, Yurko, Kateryna, Oancea, Cristian, Popov, Georgi, Smesnoi, Valentina, Placinta, Gheorghe, Kohlhof, Hella, Vitt, Daniel, Peelen, Evelyn, Mihajlović, Jelena, Muehler, Andreas R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568890/ https://www.ncbi.nlm.nih.gov/pubmed/36242741 http://dx.doi.org/10.1007/s40121-022-00690-0 |
Ejemplares similares
-
The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study
por: Muehler, Andreas, et al.
Publicado: (2019) -
Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
por: Muehler, Andreas, et al.
Publicado: (2020) -
Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases
por: Muehler, Andreas, et al.
Publicado: (2020) -
A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis
por: Fox, Robert J., et al.
Publicado: (2022) -
A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis
por: Carey, Elizabeth J., et al.
Publicado: (2022)